Search clinical trials for: erlotinib or gefitinib or icotinib

Total 5714 results

Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
Anhui Medical University

Unknown

High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

Self Efficacy | Drug Toxicity

China
Sichuan Provincial People's Hospital

Unknown

Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid) (Hybrid)

Stage IV EGFR Mutated NSCL With Brain Metastases

China
Sun Yat-sen University

Unknown

A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study (GITIC)

Gastrointestinal Cancers

China
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Thoracic Neoplasms | Non-Small-Cell Lung

China
Baylor College of Medicine

Recruiting

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population (TOKIN)

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission | Chronic Myeloid Leukemia in Remission

United States
Novartis Pharmaceuticals

Withdrawn

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

Carcinoma, Non-small Cell Lung
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China
Tian Xie
LinkDoc Technology (Beijing) Co. Ltd.

Recruiting

Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study (SELECT-2)

Adenocarcinoma | Carcinoma | Non-Small-Cell Lung Cancer

China
Qilu Hospital of Shandong University

Unknown

Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer (TCL-1)

Non-Small-Cell Lung Cancer

China
Peking University Third Hospital

Unknown

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Nonsmall Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation

Non-Small Cell Lung Cancer | Brain Metastases
Northwestern University
University of Iowa; University of Rochester; Michael J. Fox Foundation for Parkinson...

Completed

Nilotinib in Parkinson's Disease (NILO-PD)

Parkinson Disease

United States
Sichuan Provincial People's Hospital

Terminated

Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas) (Sindas)

Stage IV EGFR Mutated Non-Small Cell Lung Cancer

China
China Medical University, China
General Hospital of Shenyang Military Region; Shengjing Hospital; Liaoning Tumor... and other collaborators

Unknown

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

Non Small Cell Lung Cancer
First People's Hospital of Hangzhou

Unknown

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

Lung Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer
University of Liverpool
Imperial College London; Newcastle University; University of Glasgow

Unknown

De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia (DESTINY)

Chronic Myeloid Leukaemia

United Kingdom
Shanghai University of Traditional Chinese Medicine
Shanghai Chest Hospital; Shanghai Pulmonary Hospital, Shanghai, China

Completed

Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma

Cancer
Hangzhou Cancer Hospital

Unknown

RT Plus EGFR-TKI for Wild-type NSCLC

Non-small Cell Lung Cancer | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)

China
Amsterdam UMC, location VUmc
VitrOmics BV

Terminated

Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study (TSAP)

Advanced Solid Tumors | Metastasis | Inoperable

Netherlands
Pfizer

Completed

Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
The First Affiliated Hospital of Soochow University
Affiliated Hospital of Jiangnan University; Chia Tai Tianqing Pharmaceutical... and other collaborators

Unknown

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

Non-Small-Cell Lung

China
Seoul St. Mary's Hospital
Novartis

Unknown

Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib (RE-NICE)

Chronic Myeloid Leukemia

Korea, Republic of
Ascentage Pharma Group Inc.
HealthQuest Pharma Inc.

Active, not recruiting

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Chronic Myeloid Leukemia, Chronic Phase

China
Chinese Society of Lung Cancer
Guangdong Provincial People's Hospital

Completed

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Thoracic Neoplasms

China
Memorial Sloan Kettering Cancer Center

Terminated

Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib

Lung Cancer

United States
Fox Chase Cancer Center
Novartis

Terminated

Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Metastatic Disease | GIST

United States
Kyowa Kirin Co., Ltd.

Terminated

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib (ATTENTION)

Non-small-cell Lung Cancer

Japan
Clinical Research Center for Solid Tumor, Korea
Seoul National University Hospital; Korean Cancer Study Group

Terminated

A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Leptomeningeal Carcinomatosis

Korea, Republic of
Hoffmann-La Roche

Completed

A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC) (MERIT)

Non-Squamous Non-Small Cell Lung Cancer

Hong Kong, Spain, Russian Federation, France, Bulgaria, Germany, Estonia, Italy, Poland, Taiwan, United Kingdom, Singapore, Ireland, Belgium
Tragara Pharmaceuticals, Inc.

Completed

APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer (TP2001-201)

Recurrent Non Small Cell Lung Cancer

United States
Centro Nacional de Investigaciones Oncologicas...
Apices Soluciones S.L.; Hospital Universitario de Fuenlabrada; Grupo Hospital...

Completed

Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets

Advanced Pancreatic Carcinoma

Spain
David M. Jackman, MD
Beth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital

Completed

Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC

Non-small Cell Lung Cancer

United States
University of Alabama at Birmingham
Genentech, Inc.; OSI Pharmaceuticals

Completed

UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer (UAB0718)

Head and Neck Cancer

United States
The First Affiliated Hospital of Guangzhou Medical...

Unknown

Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC

NSCLC | EGFR Mutation

China
Henry Ford Health System
Genentech, Inc.

Terminated

Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer

Head and Neck Cancer | Carcinoma, Squamous Cell
Tianjin Medical University Cancer Institute and...

Recruiting

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC (SAINT)

Non Small Cell Lung Cancer

China
Sun Yat-sen University

Unknown

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc (NSCLC EGFR TKI)

Advanced Stage Non Small Cell Lung Cancer

China
Dana-Farber Cancer Institute
Astellas Pharma Inc

Terminated

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Non-Small Cell Lung Cancer | Epidermal Growth Factor Receptor

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Genentech, Inc.

Completed

Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

Non-small Cell Lung Cancer

United States
Ontario Clinical Oncology Group (OCOG)
Roche Pharma AG

Completed

Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL)

Non-small Cell Lung Cancer

Canada
Amsterdam UMC, location VUmc

Completed

Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Brain Metastases

Netherlands
Guangdong Provincial People's Hospital

Unknown

Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Brain Metastases
Oslo University Hospital

Terminated

Thoracal Radiotherapy and Tarceva (ThoRaT)

Cancer

Norway
SCRI Development Innovations, LLC
Bayer

Completed

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
SCRI Development Innovations, LLC
Novartis; Genentech, Inc.

Completed

Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma
Hoffmann-La Roche

Completed

A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

Australia, Hong Kong, Romania, Germany, Russian Federation, United Kingdom, Bulgaria, Malaysia, Latvia, Slovenia, Croatia, Brazil, Italy, Lithuania, India, Mexico, Singapore, Peru, Ukraine
AZ-VUB
Hoffmann-La Roche

Unknown

First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene

Lung Neoplasms | Non-Small Cell Lung Cancer | Adenocarcinoma, Bronchiolo-Alveolar

Belgium
University of Oklahoma
OSI Pharmaceuticals

Terminated

Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera (OSI-TAR-766)

Polycythemia Vera

United States
M.D. Anderson Cancer Center
United States Department of Defense

Completed

BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC

Lung Cancer

United States

Search clinical trials for: erlotinib or gefitinib or icotinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations